MUC5AC and Cholecystitis: At first glance, MUC5AC upregulation seems to be more consistent in studies on chronic cholecystitis (93–94.3% positivity in three studies using various antibodies) than studies on hepatolithiasis (17%, 40%, and 89% in three studies, respectively, using immature antibodies) [80,84,97,98,99,100].